Study summary · research use only
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study using human Leydig cells, hydrogen peroxide-induced senescent TM3 Leydig cells, and naturally aged mice, researchers examined the transcription factor FOXO4 in relation to age-related testosterone secretion insufficiency. The abstract reports that FOXO4 was specifically expressed in human Leydig cells, with nuclear translocation in elderly samples associated with decreased testosterone synthesis, and that FOXO4 was associated with maintained viability and suppressed apoptosis of senescent Leydig cells in vitro. FOXO4-DRI, a specific FOXO4 blocker that disrupts the FOXO4-p53 interaction, was associated with selective p53 nuclear exclusion and apoptosis in senescent Leydig cells, and in aged mice was associated with improvement of the testicular microenvironment and alleviation of age-related testosterone secretion insufficiency.
Abstract
Male late-onset hypogonadism is an age-related disease, the core mechanism of which is dysfunction of senescent Leydig cells. Recent studies have shown that elimination of senescent cells can restore proper homeostasis to aging tissue. In the present study, we found that the fork head box O (FOXO) transcription factor FOXO4 was specially expressed in human Leydig cells and that its translocation to the nucleus in the elderly was related to decreased testosterone synthesis. Using hydrogen peroxide-induced senescent TM3 Leydig cells as an in vitro model, we observed that FOXO4 maintains the viability of senescent Leydig cells and suppresses their apoptosis. By disrupting the FOXO4-p53 interaction, FOXO4-DRI, a specific FOXO4 blocker, selectively induced p53 nuclear exclusion and apoptosis in senescent Leydig cells. In naturally aged mice, FOXO4-DRI improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency. These findings reveal the therapeutic potential of FOXO4-DRI for the treatment of male late-onset hypogonadism.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.